Trial · NCT01080677
Caffeine/Propranolol Intervention for Acute Migraine
NCT01080677, Phase 2, Completed, Stanford University; results first posted 2017-02-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Caffeine/Propranolol Intervention for Acute Migraine. Trials, record NCT01080677. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01080677
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Caffeine/Propranolol Intervention for Acute Migraine
- NCT number
- NCT01080677
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 60 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Migraine Disorders
- Interventions
- caffeine/propranolol combination tablet, placebo
- First posted
- 2010-03-04
- Last updated
- 2017-02-24
- Results first posted
- 2017-02-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs) | 2 hours | |
| Secondary | Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol | 2 hours | |
| Secondary | Percentage of Participants Experiencing at Least One Adverse Event of Interest | 24 hours | Adverse events may have included abdominal pain, flushing, dizziness, insomnia, or anxiety |
| Secondary | Percentage of Participants With Treatment Satisfaction | 24 hours | Following up to 24 hours after treatment, participants were asked to report whether they were satisfied with level of pain relief provided by treatment |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs) | 2 hours | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol | 2 hours | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants Experiencing at Least One Adverse Event of Interest | 24 hours | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Participants With Treatment Satisfaction | 24 hours | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs) | Placebo | 10 | percentage of participants | ||
Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs) | Low Dose | 45 | percentage of participants | ||
Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe or Moderate Headache Pain at Baseline to Mild or no Pain at 2 Hrs) | High Dose | 60 | percentage of participants | ||
| Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol | Placebo | 0 | percentage of participants | ||
| Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol | Low Dose | 20 | percentage of participants | ||
| Percentage of Participants Pain Free at 2 Hrs Post First Administration of Caffeine/Propranolol | High Dose | 35 | percentage of participants | ||
| Percentage of Participants Experiencing at Least One Adverse Event of Interest | Placebo | 10 | percentage of participants | ||
| Percentage of Participants Experiencing at Least One Adverse Event of Interest | Low Dose | 25 | percentage of participants | ||
| Percentage of Participants Experiencing at Least One Adverse Event of Interest | High Dose | 50 | percentage of participants | ||
| Percentage of Participants With Treatment Satisfaction | Placebo | 5 | percentage of participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 20 | |
| Overall Study | STARTED | Low Dose | 20 | |
| Overall Study | STARTED | High Dose | 20 | |
| Overall Study | COMPLETED | Placebo | 20 | |
| Overall Study | COMPLETED | Low Dose | 20 | |
| Overall Study | COMPLETED | High Dose | 20 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Low Dose | 0 | |
| Overall Study | NOT COMPLETED | High Dose | 0 |
Source ClinicalTrials.gov
Adverse events15
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | abdominal pain | Gastrointestinal disorders | Placebo | 2 | 20 | 2 |
| other | abdominal pain | Gastrointestinal disorders | Low Dose | 1 | 20 | 1 |
| other | abdominal pain | Gastrointestinal disorders | High Dose | 1 | 20 | 1 |
| other | dizziness | Nervous system disorders | Placebo | 2 | 20 | 2 |
| other | dizziness | Nervous system disorders | Low Dose | 1 | 20 | 1 |
| other | dizziness | Nervous system disorders | High Dose | 1 | 20 | 1 |
| other | insomnia | Nervous system disorders | Placebo | 0 | 20 | 0 |
| other | insomnia | Nervous system disorders | Low Dose | 1 | 20 | 1 |
| other | insomnia | Nervous system disorders | High Dose | 1 | 20 | 1 |
| other | anxiety | Psychiatric disorders | Placebo | 0 | 20 | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Low Dose | ||
| Total, all-cause mortality | High Dose | ||
| Total, other adverse events | Placebo | 4 | 20 |
| Total, other adverse events | Low Dose | 5 | 20 |
| Total, other adverse events | High Dose | 5 | 20 |
| Total, serious adverse events | Placebo | 0 | 20 |
| Total, serious adverse events | Low Dose | 0 | 20 |
| Total, serious adverse events | High Dose | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01080677
GET https://conductscience.org/api/trials/v1/NCT01080677/registered